Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists

Vascular Pharmacology

Volumn 45, Issue 3, 2006, Pages 154-162

  Erbe, David V ^a   Gartrell, Katherine ^a   Zhang, Yan Ling ^a   Suri, Vipin ^a   Kirincich, Steven J ^a   Will, Sarah ^a   Perreault, Mylene ^a   Wang, Suyue ^a   Tobin, James F ^a  

^a PFIZER INC   (United States)

Author keywords

Angiotensin; Diabetes mellitus; Hypertension; Insulin resistance; PPAR ; Receptor pharmacology

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; GLUCOSE; INSULIN; IRBESARTAN; LOSARTAN; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; ROSIGLITAZONE; TELMISARTAN; VALSARTAN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1; PEROXISOME-PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA COACTIVATOR-1; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ASSAY; CELL FREE SYSTEM; CONTROLLED STUDY; DRUG EFFECT; FIBROBLAST; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TRANSACTIVATION; ANIMAL; BLOOD; CELL STRAIN 3T3; CERCOPITHECUS; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG POTENTIATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; INSULIN RESISTANCE; METABOLISM; MOUSE MUTANT; OBESITY; PROMOTER REGION; STRUCTURE ACTIVITY RELATION;

3T3-L1 CELLS; ADIPOGENESIS; ADIPONECTIN; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD GLUCOSE; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, OBESE; OBESITY; PPAR GAMMA; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 33750825285     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.05.002     Document Type: Article

References (27)

1. Benkirane K., Viel E.C., Amiri F., and Schiffrin E.L. Peroxisome proliferator-activated receptor g regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47 (2006) 102-108
2. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M.A., and Kurtz T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43 (2004) 993-1002
3. Clasen R., Schupp M., Foryst-Ludwig A., Sprang C., Clemenz M., Krikov M., Thone-Reineke C., Unger T., and Kintscher U. PPARγ-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46 (2005) 137-143
4. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefèbvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., and Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trial in macrovascular events: a randomized controlled clinical trial. Lancet 366 (2005) 1279-1289
5. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
6. Erbe D.V., Wang S., Zhang Y.L., Harding K., Kung L., Tam M., Stolz L., Xing Y., Furey S., Qadri A., Klaman L.D., and Tobin J.F. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol. Pharmacol. 67 (2005) 69-77
7. Ertl P., Rohde B., and Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43 (2000) 3714-3717
8. Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M.A., Oleggini M., Graziadei L., Pedrinelli R., Brandi L., and Bevilacqua S. Insulin resistance in essential hypertension. N. Engl. J. Med. 317 (1987) 350-357
9. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116 (2004) 337-350
10. Folli F., Kahn C.R., Hansen H., Bouchie J.L., and Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J. Clin. Invest. 100 (1997) 2158-2169
11. Fujimoto M., Masuzaki H., Tanaka T., Yasue S., Tomita T., Okazawa K., Fujikura J., Chusho H., Ebihara K., Hayashi T., Hosoda K., and Nakao K. An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 576 (2004) 492-497
12. Furuhashi M., Ura N., Higashiura K., Murakami H., Tanaka M., Moniwa N., Yoshida D., and Shimamoto K. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 (2003) 76-81
13. Gillespie E.L., White C.M., Kardas M., Lindberg M., and Coleman C.I. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28 (2005) 2261-2266
14. Henriksen E.J., Jacob S., Kinnick T.R., Teachey M.K., and Krekler M. Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38 (2001) 884-890
15. 1) receptor blockers in hypertension. J. Hum. Hypertens. 14 Suppl. 1 (2000) S73-S86
16. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
17. 2: implications for atherosclerotic plaque rupture. J. Leukoc. Biol. 78 (2005) 195-201
18. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., and Kahn R. Thiazolidinedione use, fluid retention, and congested heart failure. Circulation 108 (2003) 2941-2948
19. Ogihara T., Asano T., Ando K., Chiba Y., Sakoda H., Anai M., Shojima N., Ono H., Onishi Y., Fujishiro M., Katagiri H., Fukushima Y., Kikuchi M., Noguchi N., Aburatani H., Komuro I., and Fujita T. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40 (2002) 872-879
20. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the rennin-angiotensin system. Drugs 64 (2004) 2537-2565
21. Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S., Hennuyer N., Ruiz P., Unger T., Staels B., and Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54 (2005) 3442-3452
22. Schupp M., Janke J., Clasen R., Unger T., and Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109 (2004) 2054-2057
23. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
24. Velloso L.A., Folli F., Sun X.J., White M.F., Saad M.J.A., and Kahn C.R. Cross-talk between the insulin and angiotensin signaling systems. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 12490-12495
25. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 366 (2005) 1241-1242
26. Yki-Jarvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
27. Zaman M.A., Oparil S., and Calhoun D.A. Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev., Drug Discov. 1 (2002) 621-636